NCT03746535EARLY_PHASE1RecruitingAccepts Healthy Volunteers

Cardiovascular Disease Risk in Women With Endometriosis

Yale University

Start Date

7/1/2022

Completion Date

12/31/2026

Summary

To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.

Detailed Description

Our scientific premise is that in women with endometriosis, elevated cardiovascular disease risk is the result of endothelial dysfunction and chronic systemic inflammation through lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) receptor activation. This cardiovascular disease risk is exacerbated by standard estrogen suppression treatments.

Eligibility Criteria

Age Range: 18 years to 45 years

Inclusion Criteria: * Young women between the ages of 18 and 45 years (Controls); * Young women between the ages of 18 and 45 years with endometriosis. Exclusion Criteria: * Subjects who smoke * Subjects who have diabetes, * Subjects with sleep apnea or BP\>140/90 will be excluded. * Women with endometriosis and severe acute pain requiring immediate treatment will be excluded.

Interventions

DRUG

Elagolix

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Endometriosis

Locations

Yale School of Medicine

New Haven, Connecticut 06519

United States